RVPH vs. CNTX, RAPT, PRQR, INCR, CTMX, MCRB, CYBN, RNAC, RZLT, and IMAB
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Context Therapeutics (CNTX), RAPT Therapeutics (RAPT), ProQR Therapeutics (PRQR), InterCure (INCR), CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), Cybin (CYBN), Cartesian Therapeutics (RNAC), Rezolute (RZLT), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
Context Therapeutics (NASDAQ:CNTX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
Context Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 194.12%. Reviva Pharmaceuticals has a consensus price target of $16.33, suggesting a potential upside of 1,083.57%. Given Context Therapeutics' higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Context Therapeutics.
Reviva Pharmaceuticals received 3 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 89.47% of users gave Reviva Pharmaceuticals an outperform vote while only 66.67% of users gave Context Therapeutics an outperform vote.
Context Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
Reviva Pharmaceuticals' return on equity of -136.03% beat Context Therapeutics' return on equity.
Context Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 9 mentions for Reviva Pharmaceuticals and 5 mentions for Context Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.95 beat Context Therapeutics' score of 0.25 indicating that Context Therapeutics is being referred to more favorably in the media.
14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 12.3% of Context Therapeutics shares are owned by insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Reviva Pharmaceuticals beats Context Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
